2001 Cannabinoids Clinical Trials 
The Cannigma
MAY 19, 2021
In 2019, Japan approved clinical trials for Epidiolox — a cannabis derived medicine used to treat severe forms of childhood epilepsy such as Dravet and Lennox-Gastaut syndromes. In 2018, Epidolex became the first plant-derived cannabinoid prescription medicine to receive FDA approval. The future of weed legalization in Japan.
Cannabis Law Report
AUGUST 2, 2021
OTCQB: SPRCY ) a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced positive top-line results for its proprietary compound, SCI-160 in a controlled pre-clinical trial on neuropathic and post-operative pain. TEL AVIV, Israel , Aug.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
CannaTech
SEPTEMBER 16, 2018
Canada has been at the forefront of shaping much of the rhetoric surrounding cannabis since 2001. Over time extended clinical trials will continue to map out the plant’s therapeutic effects, supporting it as an alternative medicine offering relief for a long list of conditions. Changing Cannabis Conversations Worldwide.
CannaMD
AUGUST 26, 2020
A new review published by scientific journal, Pharmacology Biochemistry and Behavior , has found that marijuana cannabinoid, CBD, is a “promising” therapy for treating cocaine dependence. Exploring alternative therapies, researchers turned their attention to marijuana cannabinoid, cannabidiol – more commonly referred to as CBD.
Cannabis Law Report
APRIL 8, 2019
The Commonwealth Parliament’s legislation is in line with a trend towards medicinal legalisation across the developed world in recognition of a growing medical consensus concerning the therapeutic role that “cannabinoids” (chemical compounds derived from plants of the genus cannabis) can play in treating disease and illness.
Cannabis Law Report
NOVEMBER 24, 2021
The recreational use of cannabis is well known and attributed to its power as a psychotropic plant, specifically due to the cannabinoid tetrahydrocannabinol (THC). Only one article appeared in the MJA in 2000 and again in 2001. 2016 ; Sznitman et al. years (Atakan 2012 ). Discussion.
Cannabis Law Report
JUNE 10, 2021
Prevalence of marijuana use disorders in the United States between 2001–2002 and 2012–2013. Cannabis Cannabinoid Res. 9-tetrahydrocannabinol on driving performance: a randomized clinical trial. JAMA Pediatr. 2017;171:142–9. Article Google Scholar. Hasin DS, Saha TD, Kerridge BT, Goldstein RB, Chou SP, Zhang H, et al.
Expert insights. Personalized for you.
145 
Let's personalize your content